|
Match
|
Document |
Document Title |
|
|
US20090291882 |
COATINGS FOR DRUG DELIVERY DEVICES
A polymer coating for medical devices based on a polyolefin derivative. A variety of polymers are described to make coatings for medical devices, particularly, for drug delivery stents. The...
|
|
|
US20090291073 |
Compositions Comprising PKC-theta and Methods for Treating or Controlling Ophthalmic Disorders Using Same
Compositions for treating or controlling: (i) an eye condition, disorder, or disease, or (ii) a degeneration of a component of an optic nerve system in a subject, comprise a PKC-θ inhibitor. The...
|
|
|
US20090286824 |
Pyridine Classical Cannabinoid Compounds and Related Methods of Use
Disclosed are compounds of the formula I:
wherein R 1 , R 2 , V, W, X, Y and Z can be as defined herein. The compounds can be used in the treatment of disorders mediated by the cannabinoid...
|
|
|
US20090286823 |
CCR1 Inhibitors useful for the treatment of multiple myeloma and other disorders
The invention relates to the use of inhibitors of CCR1 for the treatment of cancers and osteolytic bone disorders. In some embodiments, the invention relates to methods for the treatment of...
|
|
|
US20090281081 |
CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR
Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an...
|
|
|
US20090274739 |
METHODS AND COMPOSITIONS FOR TREATING NEOINTIMAL HYPERPLASIA
The present invention relates to compositions containing an mTOR inhibitor, such as rapamycin or a rapamycin derivative, in combination with a PI3 kinase inhibitor and/or a leptin inhibitor,...
|
|
|
US20090274656 |
HEPATITIS C VIRUS INHIBITORS
Hepatitis C virus inhibitors are disclosed having the general formula:
wherein R 1 , R 2 , R 3 , R′, B, Y and X are described in the description. Compositions comprising the compounds...
|
|
|
US20090270441 |
MACROLIDES
The invention relates to the stabilization of poly-ene macrolides and to a particular macrolide obtained in crystalline form.
|
|
|
US20090270374 |
DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES
Bicyclic nitrogen containing compounds and their use as antibacterials.
|
|
|
US20090270371 |
QUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF MGLUR5 RECEPTOR-MEDIATED DISORDERS
Compounds of formula (I): and/or enantiomers and/or racemates and/or diastereomers and/or pharmaceutically acceptable salts thereof formed with acids or bases, to the process for their preparation,...
|
|
|
US20090269421 |
COATING MATERIAL
It is an object of the present invention to provide a coating material for a biomedical material surface which can control cell adhesiveness/non-cell adhesiveness and improve the biocompatibility...
|
|
|
US20090264423 |
SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS
The invention relates in part to molecules having certain biological activities that include, but are not limited to, inhibiting cell proliferation, modulating protein kinase activity and...
|
|
|
US20090263397 |
Combination anti-cancer therapy
The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to said patient simultaneously or sequentially a therapeutically effective...
|
|
|
US20090253733 |
RAPAMYCIN CARBONATE ESTERS
Certain embodiments include carbonate esters of rapamycin at position 42 that are synthesized by a lipase catalyzed regio-specific process. These compounds or a pharmaceutically acceptable salt...
|
|
|
US20090253732 |
Production Of Polyketides And Other Natural Products
The present invention relates to production of polyketides and other natural products and to libraries of compounds and individual novel compounds. Therefore in aspect the present invention...
|
|
|
US20090252806 |
NANOPARTICULATE TACROLIMUS FORMULATIONS
The present invention is directed to nanoparticulate tacrolimus compositions. The composition comprising tacrolimus particles having an effective average particle size of less than about 2000 nm...
|
|
|
US20090252778 |
METHODS AND DEVICES FOR REDUCING TISSUE DAMAGE AFTER ISCHEMIC INJURY
Methods and devices are provided for the delivery of therapeutic agents which reduce myocardial tissue damage due to ischemia and anti-restenotic agents which inhibit restenosis following a cardiac...
|
|
|
US20090247567 |
BENZOPYRAN AND BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE
Benzopyran and benzoxepin compounds of Formulas I and II, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful...
|
|
|
US20090247566 |
Pyrano [3,2-C] Pyridones and Related Heterocyclic Compounds as Pharmaceutical Agents for Treating Disorders Responsive to Apoptosis, Antiproliferation or Vascular Disruption, and the Use Thereof
A pharmaceutical composition comprising a pharmaceutically acceptable excipient or carrier and a compound Formula I:
or a pharmaceutically acceptable salt or prodrug thereof.
|
|
|
US20090247565 |
Tyrosine Kinase Inhibitors
The present invention relates to imidazo[1,2-a]pyrimidine derivatives, that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for...
|
|
|
US20090239895 |
Novel 3-thia-10-aza-phenanthrene derivatives
The compounds of formula I
in which A, R1, R2 and R3 have the meanings as given in the description, are novel effective PDE4 inhibitors.
|
|
|
US20090239791 |
PHARMACEUTICAL COMPOSITION CONTAINING LIPOPHILIC SUBSTANCE WHICH INHIBITS IL-2 PRODUCTION
A pharmaceutical composition comprising a lipophilic substance which inhibits IL-2 production, and a base capable of inhibiting blood exposure of the substance and delivering the substance to lymph...
|
|
|
US20090232868 |
Nitric Oxide Releasing Polymer Composition
Disclosed herein are biocompatible carbon-based nitric oxide (NO) donating polymers suitable for forming and coating medical devices. These polymers have acrylate backbones and are comprised of...
|
|
|
US20090232865 |
End-Capped Poly(Ester Amide) Copolymers
This invention relates to poly(ester amide)s (PEAs) comprising inactivated terminal amino and carboxyl groups, methods of synthesizing the inactivated PEAs and uses for them in the treatment of...
|
|
|
US20090227618 |
Carboline Derivatives Useful in the Inhibition of Angiogenesis
In accordance with the present invention, compounds that inhibit the expression of VEGF post-transcriptionally have been identified, and methods for their use provided. In one aspect of the...
|
|
|
US20090227561 |
FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF
The present invention provides a compound having a superior Smo inhibitory activity and lower toxicity, which is sufficiently satisfactory as a pharmaceutical product. The present invention...
|
|
|
US20090221626 |
AEROSOL FORMULATION FOR INHALATION CONTAINING AN ANTICHOLINERGIC AGENT
The invention relates to specific aqueous aerosol formulations that are devoid of propellant, containing one or more anticholinergic agents of formula (1), in which X represents an anion, and...
|
|
|
US20090221625 |
COSMECEUTICAL COMPOSITION
Topical compositions comprising: —a physiologically acceptable alkanediol, ether diol or diether alcohol containing up to (8) carbon atoms; —water; and—optionally an unsaturated fatty...
|
|
|
US20090221522 |
METHODS TO CORRECT GENE SET EXPRESSION PROFILES TO DRUG SENSITIVITY
The present invention comprises a treatment approach based on gene set-expression signatures that systematically connects a sample to a profile from a reference database to extrapolate the most...
|
|
|
US20090221503 |
USE OF RAPAMYCIN AND RAPAMYCIN DERIVATIVES FOR THE TREATMENT OF BONE LOSS
The present invention relates to a new use of rapamycin and rapamycin derivatives.
|
|
|
US20090216317 |
Delivery of Highly Lipophilic Agents Via Medical Devices
An apparatus and system for delivering a lipophilic agent associated with a medical device including: a medical device, a first lipophilic agent capable of penetrating a body lumen, wherein the...
|
|
|
US20090215813 |
HISTONE DEACETYLASE INHIBITORS AS IMMUNOSUPPRESSANTS
A method of preventing or suppressing an immune response or immune mediated response comprising administering an effective amount of an histone deacetylase inhibitor compound alone or in...
|
|
|
US20090215812 |
BIOMARKERS FOR EVALUATING LIKELIHOOD OF TUMOR SENSITIVITY TO AN MTOR INHIBITOR
The present invention provides compositions and methods for evaluating the likelihood that a tumor is sensitive to an mTOR inhibitor, e.g., rapamycin or a rapamycin analog. The invention provides...
|
|
|
US20090209572 |
36-Des(3-Methoxy-4-Hydroxycyclohexyl) 36-(3-Hydroxycycloheptyl) Derivatives of Rapamycin for the Treatment of Cancer and Other Disorders
The present invention relates to novel 36-des(3-methoxy-4-hydroxycyclohexyl)-36-(3-hydroxycyclohept
yl)rapamycin derivatives, methods for their production, and uses thereof. In a further aspect the...
|
|
|
US20090209527 |
Methods for Using Rapamycin Analogues in the Treatment of Neurological Disorders
The present invention provides methods for treatment of neurological disorders or complications due to stroke or head injury; benign or malignant neoplastic disease, carcinomas and adenocarcinomas;...
|
|
|
US20090208953 |
NEUROFIBROMIN PATHWAY MODULATORS
The present invention encompasses methods for treating neurofibromatosis and methods for screening for modulators of the neurofibromin pathway.
|
|
|
US20090208552 |
CROSS-LINKED FATTY ACID-BASED BIOMATERIALS
Fatty acid-based, pre-cure-derived biomaterials, methods of making the biomaterials, and methods of using them as drug delivery carriers are described. The fatty acid-derived biomaterials can be...
|
|
|
US20090208468 |
SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE
The present disclosure relates to oligodeoxynucleotides that suppress an immune response. Methods are disclosed for preventing or treating an immune-mediated disorder, such as, but not limited to,...
|
|
|
US20090197841 |
Inhalant Propellant-Free Aerosol Formulation
The invention relates to inhalant propellant-free aerosol formulations containing at least one inert, non-volatile auxiliary substance for adjusting defined droplet sizes.
|
|
|
US20090192127 |
Combination therapy comprising a diaryl urea compound and a p13, akt kinase or mtor inhibitors (rapamycins) for cancer treatment
The present invention relates to pharmaceutical compositions and combinations for treating cancer, comprising a diaryl urea compound e.g....
|
|
|
US20090191183 |
SUBSTITUTED INDOLES
Disclosed herein are substituted indole cysteinyl leukotriene receptor modulators of Formula I, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.
|
|
|
US20090188497 |
MEDICAL PRODUCT CONTAINING TIOTROPIUM
The invention discloses a medical product that may be used in a treatment of respiratory disorders.
|
|
|
US20090188496 |
INHALABLE TIOTROPIUM AND CONTAINER THEREFOR
A medical product suitable for storing and delivering a pre-metered dose of tiotropium, devices containing the same, and methods of using the same.
|
|
|
US20090182003 |
Methods and Compositions for Treatment Cell Proliferative Disorders
The present invention provides methods for treating and preventing cell proliferative disorders and conditions comprising administering to a subject resveratrol or an analog thereof.
|
|
|
US20090181927 |
BONDING TISSUES AND CROSS-LINKING PROTEINS WITH NAPHTHALIMIDE COMPOUNDS
Naphthalimide compounds are used in tissue bonding and protein cross-linking applications. When activated by an activating agent, such as light in the 400-500 nm absorption range, the naphthalimide...
|
|
|
US20090181063 |
IMPLANTABLE MEDICAL DEVICE COMPRISING A PRO-HEALING POLY(ESTER-AMIDE)
The present invention relates to implantable medical devices, in particular stents, comprising pro-healing poly(ester-amide)s.
|
|
|
US20090180986 |
TREATING UNWANTED OCULAR CONDITIONS USING AN ASCOMYCIN MACROLACTAM
The present invention provides compositions and uses of an ascomycin macrolactam for the treatment of an unwanted ocular condition occurring in a patient undergoing treatment with a therapeutically...
|
|
|
US20090176820 |
POLYMORPHIC FORMS AND PROCESS
The invention relates to a process for the manufacture of enantiomerically enriched or pure compounds of formula I
wherein R 1 , R 2 , R 3 , R 6 , R 7 and Q are defined as in claim 1 as well as...
|
|
|
US20090176819 |
39-Desmethoxy-39-Methyl Derivatives of Rapamycin
The present invention relates to novel 39-desmethoxy-39-methylrapamycin derivatives, methods for their production, and uses thereof. In a further aspect the present invention provides for the use...
|
|
|
US20090175951 |
NANOPARTICULATE COMPOSITIONS OF IMMUNOSUPPRESSIVE AGENTS
Methods for stabilizing chemical compounds, particularly pharmaceutical agents, using nanoparticulate compositions are described. The nanoparticulate compositions comprise a chemical compound, such...
|